Virios Therapeutics (VIRI) Scheduled to Post Quarterly Earnings on Thursday

Virios Therapeutics (NASDAQ:VIRI – Get Rating) is set to issue its quarterly earnings data before the market opens on Thursday, May 12th. Analysts expect the company to announce earnings of ($0.54) per share for the quarter.

Virios Therapeutics (NASDAQ:VIRI – Get Rating) last released its quarterly earnings data on Thursday, March 17th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.02). During the same quarter in the previous year, the company posted ($1.25) earnings per share. On average, analysts expect Virios Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Shares of VIRI stock traded down $0.22 on Friday, hitting $3.75. The stock had a trading volume of 5,066 shares, compared to its average volume of 11,302. The business has a 50 day moving average price of $4.82 and a 200 day moving average price of $5.33. The company has a market cap of $31.24 million, a PE ratio of -1.96 and a beta of -0.97. Virios Therapeutics has a one year low of $3.65 and a one year high of $7.45.

Several hedge funds have recently added to or reduced their stakes in VIRI. Citadel Advisors LLC bought a new stake in shares of Virios Therapeutics in the second quarter valued at about $64,000. Northern Trust Corp bought a new position in Virios Therapeutics in the fourth quarter worth about $77,000. BlackRock Inc. raised its holdings in Virios Therapeutics by 17.6% in the fourth quarter. BlackRock Inc. now owns 18,641 shares of the company’s stock worth $95,000 after purchasing an additional 2,785 shares in the last quarter. Geode Capital Management LLC raised its holdings in Virios Therapeutics by 10.4% in the third quarter. Geode Capital Management LLC now owns 20,429 shares of the company’s stock worth $108,000 after purchasing an additional 1,930 shares in the last quarter. Finally, Two Sigma Advisers LP raised its holdings in Virios Therapeutics by 15.0% in the third quarter. Two Sigma Advisers LP now owns 28,400 shares of the company’s stock worth $150,000 after purchasing an additional 3,700 shares in the last quarter. Hedge funds and other institutional investors own 11.40% of the company’s stock.

About Virios Therapeutics (Get Rating)

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.

Featured Articles